Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts
Acrivon Therapeutics, Inc. (ACRV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026 ACR-2316 P
How this was made
The 30-second read
Why it matters
Traders can use the disclosed cash balance and the stated milestone calendar to adjust near-term risk premium and event-driven positioning ahead of 2H 2026 interim analysis and 1H 2027 regulatory/confirmatory steps.
Market read
The filing provides a concrete funding runway (cash and investments of $90.0M as of June 30, 2026) and a dated catalyst path (2H 2026 interim analysis, 1H 2027 Phase 3 initiation and IND submission), which can drive event-driven repricing.
What to watch
Cash runway is extended, but the company still reports a sizable quarterly net loss and does not quantify probability of success for the upcoming interim analysis or Phase 3 start.
Background
This is an SEC Form 8-K (Item 2.02) with Q2 2026 financial results and pipeline milestone highlights for Acrivon’s lead programs ACR-368 and ACR-2316.
Ticker impact
Acrivon filed an 8-K with Q2 results plus clinical updates, including ACR-368 Phase 2b interim analysis timing and ACR-2316 randomized dose expansion details.
Near-term volatility likely around perceived probability of upcoming 2H 2026 interim readout and 1H 2027 Phase 3/IND milestones; otherwise sentiment supported by extended cash runway.
The article discloses primary, time-specific milestones (2H 2026 interim analysis, 1H 2027 Phase 3 initiation, 1H 2027 IND submission) and a quantified cash balance, which can re-rate risk for a clinical-stage name.
Market effects
Adds incremental datapoints for precision oncology small-molecule programs and phosphoproteomics-driven target/pathway selection, potentially supportive for similar platform biotechs.
Limited, primarily US biotech sentiment given Nasdaq-listed issuer and FDA milestone references.
Moderate, as the ACR-368 Phase 2b includes US and European sites, but no cross-border regulatory decision is disclosed.
Counterpoint
Clinical-stage optimism may be priced in; the update emphasizes ongoing dosing and mechanistic AACR presentations without providing new efficacy endpoints or interim results numbers in this filing.
Key entities
- companyAcrivon Therapeutics, Inc.
Clinical-stage biopharmaceutical company reporting Q2 2026 results and upcoming clinical/regulatory milestones.
- programACR-368 (prexasertib)
Selective small-molecule inhibitor in a registrational-intent Phase 2b study for serous endometrial cancer, with a prespecified interim analysis planned for 2H 2026.
- programACR-2316
Oral WEE1/PKMYT1 inhibitor in a Phase 1/2 study that has entered randomized dose expansion (120 mg and 160 mg) with AP3-guided rationale.
- regulatorFDA
Referenced for Fast Track and Breakthrough Device designations and for an IND filing planned in 1H 2027.
